Bristol-myers Squibb dividend calculator – Bristol-Myers Squibb: Don’t Miss This Dividend Opportunity!

☀️Trending News

BRISTOL-MYERS ($NYSE:BMY): Bristol-Myers Squibb is an attractive investment opportunity right now, offering investors a dividend that makes it a bargain. Its product portfolio includes drugs for the treatment of cancer, hepatitis, HIV/AIDS, and diabetes. It also produces over-the-counter medicines, nutritional supplements, and beauty products. This diversified portfolio makes Bristol-Myers Squibb a great choice for investors looking for long-term returns. This means investors can enjoy a steady source of income while also benefiting from any capital appreciation of the company’s stock.

This makes Bristol-Myers Squibb an even more attractive option for investors looking for strong returns. All in all, Bristol-Myers Squibb is a great option for investors looking to take advantage of an attractive dividend and long-term growth potential. With its diverse product portfolio and strong financial performance, now is an excellent time to invest in this company and reap the benefits of its dividend opportunity.

Dividends – Bristol-myers Squibb dividend calculator

For those who are looking for an opportunity to invest in a company with competitive dividend yields, Bristol-Myers Squibb is an attractive option. Over the last three years, the company has issued annual dividends of $2.28, $2.19, and $2.01 per share, respectively. Looking ahead, the dividend yields from 2021 to 2023 are estimated to be 3.17%, 3.13%, and 2.32%, respectively.

This gives the company an average dividend yield of approximately 2.87%, making it an attractive choice for those seeking a steady dividend income. With its long history of stable dividends and strong financial performance, this could be a great opportunity for investors who are interested in dividend stocks.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bristol-myers Squibb. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bristol-myers Squibb. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bristol-myers Squibb. More…

Key Ratios Snapshot

Some of the financial key ratios for Bristol-myers Squibb are shown below. More…

Market Price

BRISTOL-MYERS SQUIBB is presenting an amazing dividend opportunity for investors and should not be missed. On Tuesday, BRISTOL-MYERS SQUIBB stock opened at $51.6 and closed at $52.1, a 1.5% increase from its last closing price of $51.3. This presents a great opportunity for investors to capitalize on the current market conditions and potentially reap a solid return on investment. This implies that investors can expect to receive higher returns if they invest in BRISTOL-MYERS SQUIBB compared to other stocks in the same sector.

In addition, the company has a strong financial position and is expected to generate consistent cash flows in the near future. The current stock price presents an advantageous entry point for investors to take advantage of this dividend opportunity. With the potential for long-term returns, BRISTOL-MYERS SQUIBB could be the perfect choice for investors looking to diversify their portfolio and increase their potential returns. Live Quote…

Analysis

At GoodWhale, we have conducted a fundamental analysis of BRISTOL-MYERS SQUIBB. Our star chart indicates that they are a ‘rhino’ company, meaning their revenue or earnings have seen moderate growth. This means that BRISTOL-MYERS SQUIBB could be of interest to investors looking for a more moderate return. In terms of their health score, BRISTOL-MYERS SQUIBB scored 8/10 which is a good rating. This suggests that BRISTOL-MYERS SQUIBB has the capacity to sustain itself financially in times of crisis. Furthermore, BRISTOL-MYERS SQUIBB is strong when it comes to dividends, growth, and profitability. However, it is weak when it comes to assets. More…

Peers

The company was founded in 1887 and is headquartered in New York City. The company’s products are sold in over 100 countries. Bristol-Myers Squibb Co’s competitors include Merck & Co Inc, Amgen Inc, Eli Lilly and Co.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co Inc is a global health care company that offers a wide range of products and services to customers in more than 140 countries. The company has a market cap of 236.25B as of 2022 and a Return on Equity of 28.84%. Merck & Co Inc is a diversified company that operates in four main business segments: Pharmaceuticals, Vaccines, Animal Health, and Consumer Care. The company’s products include prescription and over-the-counter medicines, vaccines, biologic therapies, and consumer and animal health products. Merck & Co Inc is one of the world’s largest pharmaceutical companies and is a leading provider of health care products and services.

– Amgen Inc ($NASDAQ:AMGN)

Amgen Inc is a large biotechnology company with a market cap of 132.76B as of 2022. The company has a strong return on equity of 460.37%. The company focuses on developing and delivering therapies for serious illnesses.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company with a market cap of 312.88B as of 2022. Its return on equity is 45.88%. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products. It offers products in the areas of endocrinology, diabetes, oncology, immunology, neuroscience, and erectile dysfunction.

Summary

Bristol-Myers Squibb is an attractive investment option right now due to its high dividend yield and strong balance sheet. The company has also been able to generate strong cash flows from operations as well as a strong return on equity.

In addition, Bristol-Myers Squibb has a low debt-to-equity ratio, which indicates that it is well-positioned to manage its debt. The company has also been actively pursuing acquisitions and partnerships to expand its portfolio of products and services, which will help boost revenue growth in the future. Overall, Bristol-Myers Squibb is a good investment option for those looking for a steady dividend yield and strong long-term growth potential.